FSD Pharma Inc. | WebDisclosure

Basculer en Français

10605	Companies
225054	Keywords
153769	Articles
119094	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 2 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 3 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 3 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 3 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 3 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 3 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 3 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 3 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 06/22/2026 at 03:00, 6 hours ago

Tunkillia Pre-Feasibility Study Begins
Published on 06/20/2026 at 01:00, 2 days 8 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 2 days 9 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 3 days 4 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 3 days 7 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting

View all ACCESSWIRE

EQS Group

Published on 06/22/2026 at 08:57, 3 minutes ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
Published on 06/22/2026 at 08:47, 13 minutes ago

OHB to offer shares at EUR 300.00 per share
Published on 06/22/2026 at 08:37, 22 minutes ago

EQS-Adhoc: OHB SE resolves on up to EUR 510.7 million capital increase with subscription rights at EUR 300 per new share and upfront private placement along with Orchid Lux Hold-Co S.à r.l.
Published on 06/22/2026 at 08:35, 25 minutes ago

As K-Beauty Heats Up Amazon DE Prime Day, COSRX Leads with Up to 52% Off Bestsellers
Published on 06/22/2026 at 08:35, 25 minutes ago

Brook Auto Catch Light Introduces New Fashion White Edition

Les Echos

Published on 06/22/2026 at 08:30, 30 minutes ago

Eiffage entre en négociation exclusive avec Atlas Arteria en vue d’acquérir la concession du tunnel de Warnow à Rostock, en Allemagne
Published on 06/22/2026 at 08:30, 30 minutes ago

Eiffage enters into exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany
Published on 06/19/2026 at 19:33, 2 days 13 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days 13 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days 13 hours ago

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026

View all LES ECHOS COMFI WIRE